ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 66

Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators

Christina Charles-Schoeman1, Ani Shahbazian2, Jennifer Wang3, Xiaoyan Wang2, Ernest Brahn2, Jeremy Papesh2, Victor Grijalva4 and Srinivasa T. Reddy2, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, CA, 3University of California Los Angeles, Los Angeles, CA, 4Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: paraoxonase and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Animal Models Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid peroxidation and oxidative stress have been implicated in the pathogenesis of rheumatoid arthritis (RA), and we previously reported decreased inflammatory arthritis activity in PON1 transgenic (Tg) mice in 2 RA mouse models. The current work evaluated mechanisms for decreased inflammatory arthritis in PON1Tg mice using the K/BxN serum transfer model of RA.

Methods:

The K/BxN serum transfer-induced arthritis model (STIA) was used in B6 mice homozygous for the PON1 human transgene [PON1Tg] and wild type littermate control mice [WT] (n= 10 per group). Non-STIA PON1Tg (n= 9) and WT (n=10) mice were also evaluated. Liquid chromatography–electrospray ionization, tandem mass spectroscopy was performed for a panel of 13 circulating bioactive lipid mediators (BLM) including TXB2, 6tl 2epi LTB4, LTB4, 15d-D12,14 PGJ2, 13 HODE, 9 HODE, 17S-HDHA, 15 HETE, 14 S-HDHA, 11 HETE, 12 HETE, 5 HETE, and 5-oxoETE. Next-generation RNA sequencing analysis was done on liver tissue. Histopathologic scoring of arthritic hind limbs was performed by a blinded reviewer as were the prior clinical arthritis activity scores.

Results:

Marked reduction in histologic damage was observed in PON1Tg compared to WT mice (p values<0.0002; see Table) consistent with decreases in clinical arthritis scores. WT mice had significant increases in the majority of BLMs (11/13) after arthritis induction, however, PON1Tg mice did not have similar increases, and had significantly lower levels of 9/13 BLMs post-arthritis induction compared to WT mice (Table). Significant correlations were evident between lower levels of BLMs and lower clinical and histologic scores (r values = 0.5 – 0.8, p values < 0.05) for 10/13 BLMs. The hepatic glutathione metabolism pathway was 14-fold upregulated in PON1Tg mice versus WT mice after arthritis induction, controlling for baseline (non-arthritic) expression differences in PON1Tg and WT mice (Bonferroni p value < 1.5E-04). Increased expression of 7/8 genes in this pathway was significantly associated with decreases in circulating BLMs (r values = -0.5 – 0.8, p values <0.05; correlations of raw gene expression counts/various BLMs). Upregulation of GSTM3 (glutathione S-transferase mu 3 ) was highly correlated with both lower histologic damage scores (r = -0.8 – 0.9, p values <0.05) as well as trended with decreased clinical arthritis scores (r = -0.6, p = 0.09).

Conclusion:

Overexpression of the human PON1 transgene in the KBxN STIA model of RA suppressed inflammatory arthritis, which correlated with upregulation of the hepatic glutathione pathway and reduction of circulating BLMs. Further investigation of these findings is warranted to evaluate potentially novel therapeutic targets for treatment of RA.

PON1Tg

WT

Pre-arthritis

TXB2

1.87±1.02

1.71± 0.82

6tl 2epi LTB4

0.17 ± 0.09 #

0.16 ± 0.10 #

LTB4

0.19 ± 0.04 #

0.16 ± 0.03 #

15d-Dl2,14 PGJ2

0.73 ± 0.29 *

0.43 ± 0.14 #

13 HODE

9.28 ± 5.49

6.83 ± 3.44 #

9 HODE

6.31 ± 2.91

3.84 ± 2.85 #

17S-HDHA

2.38 ± 1.98 #

2.27 ± 2.14 #

15 HETE

0.41 ± 0.30

0.99 ± 0.48

14 S-HDHA

17.35 ± 10.15 #

13.99 ± 14.49 #

11 HETE

0.63 ± 0.20

0.45 ± 0.22 #

12 HETE

33.62 ± 25.95 #

24.48 ± 18.11 #

5 HETE

3.51 ± 1.98 *

1.52 ± 0.89 #

5-oxoETE

0.73 ± 0.50

0.34 ± 0.26 #

PON1Tg

WT

Post-arthritis

Inflammation (0-5)

1.5 ± 1.0*

4.5 ± 0.7

Cartilage Damage (0-5)

1.3 ± 0.9*

3.6 ± 0.8

Bone Erosion (0-5)

0.9 ± 0.9*

3.7 ± 0.9

TXB2

1.98 ± 0.52

2.32 ± 0.97

6t12epi LTB4

0.42 ± 0.16

0.54 ± 0.24

LTB4

0.25 ± 0.04 *

0.32 ± 0.06

15d-D12,14 PGJ2

0.69 ± 0.24 *

1.15 ± 0.45

13 HODE

5.29 ± 2.79 *

14.38 ± 7.81

9 HODE

4.72 ± 1.69 *

12.34 ± 4.56

17S-HDHA

7.28 ± 4.19 *

13.22 ± 3.66

15 HETE

0.77 ± 0.39 *

2.45 ± 1.41

14 S-HDHA

50.86 ± 19.66

62.45 ± 15.37

11 HETE

0.73 ± 0.27 *

1.35 ± 0.37

12 HETE

64.50 ± 30.52

69.21 ± 20.85

5 HETE

4.34 ± 2.16 *

8.19 ± 2.40

5-oxoETE

0.75 ± 0.21 *

2.92 ± 3.27

Units are ng/ml (BLMs). PON1Tg= mice homozygous for the PON1 human transgene. WT= wild type littermate control mice. *p<0.05 compared to WT. # p<0.05 compared to Post-arthritis value of same group.


Disclosure: C. Charles-Schoeman, Bristol Myers Squibb, AbbVie, Octapharma, and Pfizer, 2,Regeneron-Sanofi, Pfizer, Octapharma, Amgen, and Gilead, 5; A. Shahbazian, None; J. Wang, None; X. Wang, None; E. Brahn, None; J. Papesh, None; V. Grijalva, None; S. T. Reddy, None.

To cite this abstract in AMA style:

Charles-Schoeman C, Shahbazian A, Wang J, Wang X, Brahn E, Papesh J, Grijalva V, Reddy ST. Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/suppression-of-inflammatory-arthritis-in-human-paraoxonase-1-transgenic-mice-correlates-with-upregulation-of-the-hepatic-glutathione-pathway-and-reduction-of-bioactive-lipid-mediators/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppression-of-inflammatory-arthritis-in-human-paraoxonase-1-transgenic-mice-correlates-with-upregulation-of-the-hepatic-glutathione-pathway-and-reduction-of-bioactive-lipid-mediators/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology